What is electroCore, Inc.'s market cap?

electroCore, Inc. (ECOR) has a market capitalization of $50.2M and trades on NASDAQ.

What is electroCore, Inc.'s revenue and profitability?

electroCore, Inc. generated $34.9M in trailing twelve-month revenue with a net loss of $15.4M, representing a net margin of -44.1%. Gross margin stands at 87.2%, with free cash flow of -$6.9M. These figures are based on the Q1 2026 filing.

Who are electroCore, Inc.'s competitors?

electroCore, Inc.'s key competitors include Eli Lilly and Company, AbbVie, Alphabet Inc., and others. These companies compete in similar markets and product categories.

Who does electroCore, Inc. partner with?

electroCore, Inc.'s notable partners include Lovell Government Services, Best Buy, Rehabmart, and others.

What subsidiaries does electroCore, Inc. have?

electroCore, Inc.'s subsidiaries include NeuroMetrix, electroCore U.K. Ltd., electroCore Germany GmbH.

Where is electroCore, Inc. headquartered?

electroCore, Inc. is headquartered in United States of America and employs approximately 62 people. It has been publicly traded since 2018.

electroCore, Inc.

ECOR

electroCore is a bioelectronic technology company focused on developing and commercializing non-invasive vagus nerve stimulation (nVNS) and neuromodulation therapies.

Market cap

$50.19M-4.2%

Revenue$34.9M+31.9%

Net income-$15.4M-25.7%

Free cash flow-$6.9M+64.1%

EPS (diluted)-$1.77-13.5%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 6, 2026

Revenue$9.6MBeat by $572.4K EPS-$0.59In line

Read the full report

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$9.5M

EPS estimate-$0.41

Financials

Q1 2026

Income statement

See full

Revenue$9.6M+42.6%

Gross profit$8.4M+46.6%

Operating income-$5.3M-39.1%

Net income-$5.3M-36.7%

EPS (diluted)-$0.59-25.5%

Balance sheet

See full

Cash & equivalents$4.9M+20.5%

Total debt$9.5M+127%

Total equity-$5.7M-230%

Total assets$15.5M-3.5%

Cash flow

See full

Operating cash flow-$3.0M+30.9%

CapEx$2.0K-94.6%

Free cash flow-$3.0M+31.5%

Valuation & ratios

Valuation

See full

Market cap$50.19M-4.2%

Enterprise value$54.82M+1.0%

P/S1.4×-0.5×

Profitability

See full

Gross margin87.2%+2.0pp

Operating margin-42%-3.3pp

Net margin-44.1%-2.0pp

FCF margin-19.7%—

Returns & leverage

See full

Current ratio1×-0.5×

Segments

By segment

See full

Bioelectronic Innovations$9.6M+42.6%

By product

See full

License$17.0K+13.3%

Competitors

By market cap

Apple$4.95T+54.8%

Alphabet Inc.$3.99T+70.7%

Amazon$2.49T+0.7%

Eli Lilly$1.07T+47.2%

AbbVie$453.91B+36.3%

Neuraxis$83.5M+223%

electroCore, Inc.$50.2M-6.5%

Nexalin Technology, Inc.$9.7M-49.9%

By revenue growth

Eli Lilly+47.4%

electroCore, Inc.+31.9%

By net margin

Alphabet Inc.54.77%+23.7pp

Eli Lilly34.99%+12.3pp

Apple27.15%+2.8pp

Amazon10.65%+0.5pp

AbbVie5.79%-1.5pp

electroCore, Inc.-44.08%+2.2pp

Profile

electroCore is a bioelectronic technology company focused on developing and commercializing non-invasive vagus nerve stimulation (nVNS) and neuromodulation therapies. The company provides proprietary handheld and wearable devices designed to treat primary headache conditions, chronic pain, and fibromyalgia, while also offering consumer products for general wellness and human performance. Its core value proposition lies in providing non-invasive, drug-free alternatives to traditional pharmaceutical treatments for neurological and chronic pain disorders.

Competitive position

The company is a pioneer in non-invasive vagus nerve stimulation with a significant patent portfolio and established government contracts, though it faces competition from large pharmaceutical firms and emerging neuromodulation device makers.

GeographiesUnited States, United Kingdom, European Economic Area

Customer segmentsGovernment healthcare agencies, Chronic pain patients, Military and defense, Wellness-conscious consumers

Business modelDirect-to-consumer, B2B2C, Government contracting, Razor-and-blade (device and refills)

SuppliersThird-party contract manufacturers, Electronic component suppliers, Software developers, Specialty pharmacies

CustomersU.S. Department of Veterans Affairs, U.S. Department of Defense, UK National Health Service, Retailers like Best Buy, Direct-to-consumer patients

CountryUnited States of America

Listed2018

Employees62.0

CEOThomas J. Errico

SectorHealthcare

IndustryMedical - Devices

Websiteelectrocore.com

FilingsSEC EDGAR

Ask your AI about electroCore, Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is electroCore, Inc.'s market cap?: electroCore, Inc. (ECOR) has a market capitalization of $50.2M and trades on NASDAQ.
What is electroCore, Inc.'s revenue and profitability?: electroCore, Inc. generated $34.9M in trailing twelve-month revenue with a net loss of $15.4M, representing a net margin of -44.1%. Gross margin stands at 87.2%, with free cash flow of -$6.9M. These figures are based on the Q1 2026 filing.
Who are electroCore, Inc.'s competitors?: electroCore, Inc.'s key competitors include Eli Lilly and Company, AbbVie, Alphabet Inc., and others. These companies compete in similar markets and product categories.
Who does electroCore, Inc. partner with?: electroCore, Inc.'s notable partners include Lovell Government Services, Best Buy, Rehabmart, and others.
What subsidiaries does electroCore, Inc. have?: electroCore, Inc.'s subsidiaries include NeuroMetrix, electroCore U.K. Ltd., electroCore Germany GmbH.
Where is electroCore, Inc. headquartered?: electroCore, Inc. is headquartered in United States of America and employs approximately 62 people. It has been publicly traded since 2018.